Vincristine-induced neurotoxicity in pediatric patients with rhabdomyosarcoma: A retrospective analysis of clinical features and outcome

Lama Dakika Faculty of Medicine, American University of Beirut, Beirut, Lebanon

Maya Basbousb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Hani Tamimc Clinical Research Institute, American University of Beirut Faculty of Medicine, Beirut, Lebanon

https://orcid.org/0000-0002-2019-4362

Yacoub Moubarakb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Nidale Tarekb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Dima Hamidehb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Samar Muwakkitb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Miguel Abboudb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon

Raya Saabb Department of Pediatrics, Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, LebanonCorrespondence[email protected]

https://orcid.org/0000-0001-5776-2303

show all

Abstract

Vincristine is an essential component of rhabdomyosarcoma treatment. However, it can cause motor neurotoxicity, necessitating dose reductions. We retrospectively reviewed the rates and patterns of vincristine-induced motor neuropathy in children treated for rhabdomyosarcoma, and investigated effects on outcome. Fifteen of 43 patients (35%) developed motor neuropathies necessitating dose reductions, which ranged from 1.7% to 58% of planned cumulative dose. Older age was the only significant clinical risk factor. Almost half (47%) recovered during treatment with subsequent dose escalation. Most patients had complete resolution of symptoms upon follow-up. There was no discernible effect of treatment reduction on survival or relapse rates.

Keywords:

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Vincristine-induced neurotoxicity in pediatric patients with rhabdomyosarcoma: A retrospective analysis of clinical features and outcome

Information for

Open access

Opportunities

Help and information

Vincristine-induced neurotoxicity in pediatric patients with rhabdomyosarcoma: A retrospective analysis of clinical features and outcome

Abstract

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature